Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors: Correlation with histological subtype and clinical outcome

American Journal of Pathology

Volumn 148, Issue 5, 1996, Pages 1531-1541

  Przygodzki, Ronald M ^a   Finkelstein, Sydney D ^b   Langer, John C ^c   Swalsky, Patricia A ^b   Fishback, Nancy ^a   Bakker, Anke ^b   Guinee, Donald G ^a   Koss, Michael ^a   Travis, William D ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; RAF PROTEIN;

ARTICLE; EXON; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; METASTASIS; NEUROENDOCRINE TUMOR; ONCOGENE RAS; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

CARCINOID TUMOR; CARCINOMA, NEUROENDOCRINE; CARCINOMA, SMALL CELL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EXONS; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; NEUROENDOCRINE TUMORS; POINT MUTATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029983299     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GJ, Nieman L, Chrousos G, Pass H, Doppman J: Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma, an ultrastructural, immunohistochemical, and flow cytometric study of 35 cases Am J Surg Pathol 1991, 15 529-553
2. Arrigoni MG, Woolner LB, Bernatz PE: Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg 1972, 64:413-421
3. Kogan EA, Mazurenko NN, Sekamova SM. Expression of cell oncogenes, DNA content and cell heterogeneity in human lung cancer (meeting abstract) J Cancer Res Clin Oncol 1991, 117(Suppl 3):S118
4. Carbone DP, Mitsudomi T, Rusch V, Nowak JA, McIntire D, Chiba I, Gazdar AF, Minna JD p53 protein overexpression, but not gene mutation, is predictive of significantly shortened survival in resected non-small cell lung cancer (NSCLC) patients (meeting abstract) Proc Annu Meet Am Soc Clin Oncol 1993, 12:A1112
5. Barbareschi M, Girlando S, Mauri FA, Arrigoni G, Laurino L, Dalla PP, Doglioni C: Tumour suppressor gene products, proliferation, and differentiation markers in lung neuroendocrine neoplasms J Pathol 1992, 166:343-350
6. Bohm J, Kacic V, Gais P, Prauer HW, Hofler H: Prognostic value of nucleolar organizer regions in neuroendocrine tumours of the lung Histochemistry 1993, 99: 85-90
7. Johnson BE, Kelley MJ: Overview of genetic and molecular events in the pathogenesis of lung cancer Chest 1993: 103 1S-3S
8. Sameshima Y, Matsuno Y, Hirohashi S, Shimosato Y, Mizoguchi H, Sugimura T, Terada M, Yokota J Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. Oncogene 1992, 7:451-457
9. D'Amico D, Carbone D, Mitsudomi T, Nau M, Fedorko J, Russell E, Johnson B, Buchhagen D, Bodner S, Phelps R: High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 1992, 7:339-346
10. World Health Organization. Histologic typing of lung tumors, ed 2 International Histologic Classification of Tumours, vol 77. Geneva, World Health Organization, 1982
11. Colby TV, Koss MN, Travis WD: Carcinoid and other neuroendocrine tumors. Tumors of the Lower Respiratory Tract. Washington, DC, Armed Forces Institute of Pathology, 1995, pp 287-309
12. Hirsch FR, Matthews MJ, Aisner S, Campobasso O, Elema JD, Gazdar AF, Mackay B, Nasiell M, Shimosato Y, Steele RH, Yesner R, Zettergren L Histopathologic classification of small cell lung cancer, changing concepts and terminology. Cancer 1988, 62:973-977
13. Finkelstein SD, Sayegh R, Christensen S, Swalsky PA: Genotypic classification of colorectal adenocarcinoma, biologic behavior correlates with K-ras-2 mutation type Cancer 1993, 71 3827-3838
14. Finkelstein SD, Sayegh R, Bakker A, Swalsky PA: Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis Arch Surg 1993, 128:526-531
15. Gerwin BI, Reddel RR, Ke Y, Pfeifer AM, Forrester K, Lehman T, Spillare E, Kispert J, Murakami M, Masui T: Utilization of SV40 T antigen 'immortalized' human bronchial epithelial cells for studies of positive and negative growth controls (meeting abstract). Workshop on Neoplastic Transformation in Human Cell Systems in Vitro: Mechanisms of Carcinogenesis, April 1991, S30
16. Storm SM, Rapp UR: Oncogene activation: c-raf-1 gene mutation in experimental and naturally occurring tumors Toxicol Lett 1993, 67:201-210
17. Pfeifer AM, Mark GE, Malan SL, Graziano S, Amstad P, Harris CC. Cooperation of c-raf-1 and c-myc protooncogenes in the neoplastic transformation of simian virus 40 large tumor antigen-immortalized human bronchial epithelial cells. Proc Natl Acad Sci USA 1989, 86:10075-10079
18. Urban T, Ricci S, Lacave R, Kambouchner M, Capron F, Bernaudin JF: Evaluation of K-Ras codon 12 mutation in lung adenocarcinoma and neighboring bronchial mucosa by a rapid and sensitive nonradioactive PCR amplification (meeting abstract). Eur Respir J 1992, 5(Suppl 15):27S-28S
19. Harris CC, Reddel R, Pfeifer A, Iman D, McMenamin M, Trump BF, Weston A: Role of oncogenes and tumour suppressor genes in human lung carcinogenesis. Iarc Sci Publ 1991, 105 294-304
20. Lehman TA, Reddel R, Pfeifer AM, Spillare E, Kaighn ME, Weston A, Gerwin BI, Harris CC. Oncogenes and tumor-suppressor genes. Environ Health Perspect 1991, 93 133-134
21. Takahashi T, Takahashi T, Suzuki H, Hida T, Sekido Y, Ariyoshi Y, Ueda R: The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 1991, 6 1775-1778
22. Takahashi T, Carbone D, Takahashi T, Nau MM Hida T, Linnoila I, Ueda R, Minna JD. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 1992, 52:2340-2343
23. Takiguchi Y, Takahashi Y, Kuriyama T, Miyamoto T: NIH 3T3 transfectant containing human k-ras oncogene shows enhanced metastatic activity after in vivo tumor growth or co-culture with fibroblasts, Clin Exp Metastasis 1992, 10:351-360
24. Brambilla E, Gazzeri S, Moro D, Caron de Fromentel C, Gouyer V, Jacrot M, Brambilla C: Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 1993, 143:199-210
25. Iggo R, Gatter K, Bartek J, Lane D, Harris AL Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990, 335 675-679
26. Roncalli M, Doglioni C, Springall DR, Papotti M, Pagani A, Polak JM, Ibrahim NB, Coggi G, Viale G Abnormal p53 expression in lung neuroendocrine tumors: diagnostic and prognostic implications. Diagn Mol Pathol 1992, 1:129-135
27. Lohman DR, Fesseler B, Putz B, Reich U, Bohm J, Prauer H, Wunsch PH, Hofler H: Infrequent mutations of the p53 gene in pulmonary carcinoid tumors. Cancer Res 1993, 53:5797-5801
28. Gazzeri S, Brambilla E, Caron de Fromentel C, Gouyer V, Moro D, Perron P, Berger F, Brambilla C: p53 genetic abnormalities and myc activation in human lung carcinoma Int J Cancer 1994, 58:24-32
29. Hiyama K, Hasegawa K, Ishioka S, Takahashi N Yamakido M An atypical carcinoid tumor of the lung with mutations in the p53 gene and the retinoblastoma gene. Chest 1993, 104 1606-1607
30. Matlashewski G, Banks L, Pim D, Crawford L. Analysis of human p53 proteins and mRNA levels in normal and transformed cells Eur J Biochem 1986, 154:665-672
31. Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, Fedorko J, Buchhagen DL, Nau MM, Gazdar AF: Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992, 7:743-749
32. Minna J, D'Amico D, Broers J, Buchhagen D, Carbone D, Chiba I, Curial D, Kaye F, Linnoila I, Maneckjee R The molecular pathogenesis of lung cancer (meeting abstract) Br J Cancer 1990, 62(Suppl 11) 3
33. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991, 253 49-53
34. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? Revisited. J Pathol 1994 172:1-4
35. Lane DP. p53 and human cancers Br Med Bull 1994 50:582-599
36. Lane DP: p53, guardian of the genome. Nature 1992, 358:15-16
37. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA, Cote RJ Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994, 331:1259-1264
38. Cagle PT, Brown RW, Lebovitz RM: p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. Hum Pathol 1994, 25 443-448
39. Lianes P, Orlow I, Zhang ZF, Oliva MR, Sarkis AS, Reuter VE, Cordon Cardo C. Altered patterns of MDM2 and TP53 expression in human bladder cancer J Natl Cancer Inst 1994, 86 1325-1330
40. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein mdm2 conceals the activation domain of tumour suppressor p53. Nature 1993, 362:857-860
41. Momand J, Zambetti GP, Olson DC, George D, Levine AJ The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245
42. Warren WH, Memoli VA, Gould VE: Immunohistochemical and ultrastructural analysis of bronchopulmonary neuroendocrine neoplasms. II. Well-differentiated neuroendocrine carcinomas. Ultrastruct Pathol 1984, 7:185-199
43. Mark EJ, Ramirez JF Peripheral small-cell carcinoma of the lung resembling carcinoid tumor: a clinical and pathologic study of 14 cases Arch Pathol Lab Med 1985, 109:263-269
44. Wagner SN, Muller R, Boehm J, Putz B, Wunsch P, Hofler H. Neuroendocrine neoplasms of the lung are not associated with point mutations at codon 12 of the Ki-ras gene Virchows Arch B Cell Pathol 1993, 63:325-329
45. Salomons GS, Slebos RJ, Groot P, Evers SG, Rodenhuis S Absence of point-mutations in the c-raf-1 oncogene in human non-small cell lung carcinomas (NSCLC), in a region frequently altered in carcinogen-induced mouse lung tumors (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 1992, 33:A2135
46. Rodenhuis S, van de Watering ML, Mooi WJ, Evers SG, van ZN, Bos JL: Mutational activation of the k-ras oncogene a possible pathogenetic factor in adenocarcinoma of the lung N Engl J Med 1987, 317 929-935
47. Rodenhuis S, Slebos RJ. The ras oncogenes in human lung cancer. Am Rev Respir Dis 1990, 142 s27-s30
48. Rodenhuis S, Slebos RJ: Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992, 52 2665s-2669s
49. Heighway J, Hasleton PS. C-ki-ras amplification in human lung cancer Br J Cancer 1986, 53:285-287
50. Slebos RJC, Rodenhuis S: The molecular genetics of human lung cancer. Eur Respir J 1989, 2:461-469
51. Wagner SN, Muller R, Boehm J, Putz B, Wunsch PH, Hofler H. Neuroendocrine neoplasms of the lung are not associated with point mutations at codon 12 of the Ki-ras gene. Virchows Arch B Cell Pathol Incl Mol Pathol 1993, 63:325-329
52. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna J p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992, 7:171-180
53. Laborda J, Sausville EA, Hoffman T, Notario V dlk, a putative mammalian homeotic gene differentially expressed in small cell lung carcinoma and neuroendocrine tumor cell line. J Biol Chem 1993, 268:3817-3820
54. Doyle LA, Mabry M, Stahel RA, Waibel R, Goldstein LH: Modulation of neuroendocrine surface antigens in oncogene-activated small cell lung cancer lines Br J Cancer Suppl 1991, 14:39-42